<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237315</url>
  </required_header>
  <id_info>
    <org_study_id>RDCRN 5101</org_study_id>
    <secondary_id>U54RR019453</secondary_id>
    <secondary_id>U54HD061221</secondary_id>
    <nct_id>NCT00237315</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of Urea Cycle Disorders</brief_title>
  <official_title>Longitudinal Study of Urea Cycle Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrea Gropman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urea cycle disorders (UCD) are a group of rare inherited metabolism disorders. Infants and
      children with UCD commonly experience episodes of vomiting, lethargy, and coma. The purpose
      of this study is to perform a long-term analysis of a large group of individuals with various
      UCDs. The study will focus on the natural history, disease progression, treatment, and
      outcome of individuals with UCD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urea cycle disorders are a group of rare genetic diseases that affect how protein is broken
      down in the body. UCDs are caused by a deficiency in one of six enzymes or two mitochondrial
      membrane transporters responsible for removing ammonia, a waste product of protein
      metabolism, from the bloodstream. Normally, ammonia is converted into urea and then removed
      from the body in the form of urine. In UCDs, however, ammonia accumulates unchecked and is
      not removed from the body. It then reaches the brain through the blood, where it causes
      irreversible brain damage and/or death.

      All UCDs, except for one (ornithine transcarbamylase deficiency), are inherited as recessive
      traits. The purpose of this study is to perform a long-term analysis of a large group of
      individuals with various UCDs. Biochemical status, growth, and cognitive function will be
      assessed. Survival and cognitive outcome of the two most commonly used forms of treatment,
      alternate pathway therapy and transplantation, will be evaluated. In addition, this study
      will identify the biochemical changes that may predict future metabolic imbalances so that
      they may be corrected before clinical symptoms develop.

      This observational study is funded through 2019. All participants will attend an initial
      study visit, which will include a medical and diet history, physical and neurological
      examinations, psychological testing, and blood tests. Participants will then be followed with
      subsequent study visits, which will last 2-3 hours each. Individuals with neonatal onset UCD
      will be assessed every 3 months until age 2 and every 6 months thereafter. Individuals with
      late onset UCD will be evaluated every 6 months. Psychological testing will take place every
      2 years. Psychological testing will take from 30 minutes (for younger children) up to 3
      hours, depending on test battery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of specific morbid indicators of disease severity</measure>
    <time_frame>End of study</time_frame>
    <description>hyperammonemia, developmental disabilities, long-term renal and hepatic effects, and case-fatality associated with the various forms of UCD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between various biomarkers and disease severity and progression</measure>
    <time_frame>End of study</time_frame>
    <description>correlation between glutamine, ammonia, liver function (biomarkers) and severity scale and IQ in terms of outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and efficacy of currently used and new UCD therapies</measure>
    <time_frame>End of study</time_frame>
    <description>Interim events related to treatments (drugs, diet or liver transplant)</description>
  </primary_outcome>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Brain Diseases, Metabolic, Inborn</condition>
  <condition>Amino Acid Metabolism, Inborn Errors</condition>
  <condition>Urea Cycle Disorders</condition>
  <eligibility>
    <study_pop>
      <textblock>
        &gt;550 individuals with urea cycle disorders, up to a total of 1,100 enrolled
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of NAGS deficiency, defined as the detection of a pathogenic mutation,
             and/or decreased (less than 20 % of control) NAGS enzyme activity in liver ,and/or
             hyperammonemia and first degree relative meets at least one of the criteria for NAGS
             deficiency

          -  Diagnosis of CPS I deficiency, defined as decreased (less than 20 % of control) CPS I
             enzyme activity in liver, and/or an identified pathogenic mutation, and/or
             hyperammonemia and first degree relative meets at least one of the criteria for CPS I
             deficiency

          -  Diagnosis of OTC deficiency, defined as the identification of a pathogenic mutation,
             and/or less than 20% of control of OTC activity in the liver, and/or elevated urinary
             orotate (greater than 20 uM/mM) in a random urine sample or after allopurinol
             challenge test, and/or hyperammonemia and first degree relative meets at least one of
             the criteria for OTC deficiency

          -  Diagnosis of AS deficiency (Citrullinemia), defined as a greater than or equal to
             10-fold elevation of citrulline in plasma, and/or decreased AS enzyme activity in
             cultured skin fibroblasts or other appropriate tissue, and/or identification of a
             pathogenic mutation in the AS gene, and/or hyperammonemia and first degree relative
             meets at least one of the criteria for AS Deficiency

          -  Diagnosis of AL deficiency (Argininosuccinic Aciduria, ASA), defined as the presence
             of argininosuccinic acid in the blood or urine, and/or decreased AL enzyme activity in
             cultured skin fibroblasts or other appropriate tissue, and/or identification of a
             pathogenic mutation in the AL gene, and/or hyperammonemia and first degree relative
             meets at least one of the criteria for AL Deficiency

          -  Diagnosis of ARG deficiency (Hyperargininemia), defined as a greater than or equal to
             5-fold elevated arginine levels in the blood, and/or decreased arginase enzyme levels
             in red blood cells or other appropriate tissue, and/or identification of a pathogenic
             mutation in the ARG gene, and/or hyperammonemia and first degree relative meets at
             least one of the criteria for ARG Deficiency

          -  Diagnosis of HHH Syndrome or ORNT deficiency, defined as a greater than or equal to
             5-fold elevated plasma ornithine and homocitrulline levels in the urine, and/or a
             pathogenic mutation, and/or less than 20% residual labeled ornithine incorporation
             into protein in cultured fibroblasts, and/or hyperammonemia and first degree relative
             meets at least one of the criteria for HHH Syndrome or ORNT Deficiency

          -  Diagnosis of CITR deficiency (Citrullinemia Type II), defined as elevated citrulline
             levels in the blood and a pathogenic mutation and/or hyperammonemia and first degree
             relative meets criteria for CITR Deficiency

          -  Pending diagnosis of a UCD (UCD highly likely), defined as laboratory values highly
             suggestive of a UCD with symptomatic hyperammonemic episodes but without a verifiable
             diagnosis

        Exclusion Criteria:

          -  Hyperammonemia caused by an organic academia, lysinuric protein intolerance,
             mitochondrial disorder, congenital lactic academia, fatty acid oxidation defects, or
             primary liver disease

          -  Rare and unrelated comorbidities (e.g., Down's syndrome, intraventricular hemorrhage
             in the newborn period, and extreme prematurity)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Gropman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shawn McCandless, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandesh CS Nagamani, MD, FACMG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Seminara, MPH</last_name>
    <phone>202-306-6489</phone>
    <email>jseminar@childrensnational.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Singer, MS, LCGC</last_name>
      <phone>310-206-7470</phone>
      <email>RSigner@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Cederbaum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Derek Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vimal Vimal Gunasekaran</last_name>
      <email>Vimal.Gunasekaran@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Renata C Gallagher, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thu Quan, MBA, HCM</last_name>
      <phone>650-736-8166</phone>
      <email>tquan@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Enns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Coughlin, MS, CGC</last_name>
      <phone>303-724-2310</phone>
      <email>Coughlin.Curtis@tchden.org</email>
    </contact>
    <investigator>
      <last_name>James Weisfeld-Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Curtis Coughlin, MS, CGC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Simpson, MS, CGC</last_name>
      <phone>202-476-6216</phone>
      <email>ksimpson@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas Ah Mew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston (UCDC New England Center)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Anastasoaie</last_name>
      <phone>617-355-7346</phone>
      <email>Vera.Anastasoaie@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Waisbren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harvey Levy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Elsbecker, MS, RN, CPNP</last_name>
      <phone>612-626-5275</phone>
      <email>selsbeck10@umphysicians.umn.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Fierro</last_name>
      <phone>212-659-1477</phone>
      <email>luca.fierro@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>George A. Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Medical College</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Lynn, PhD</last_name>
      <phone>216-844-7124</phone>
      <email>Audrey.Lynn@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Shawn McCandless, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sondra Bloxam</last_name>
      <phone>503-494-4290</phone>
      <email>bloxam@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Cary Harding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irma Payan, RN</last_name>
      <phone>215-590-6236</phone>
      <email>Payan@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Yudkoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Mullins, RN, BSN</last_name>
      <phone>832-822-4263</phone>
      <email>mullins@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Sandesh Nagamani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linnea Brody, BS, MPH</last_name>
      <phone>206-987-3694</phone>
      <email>linnea.brody@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Lawrence Merritt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liora Caspi</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>328027</phone_ext>
      <email>liora.caspi@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Andreas Schulze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Burgard, PhD</last_name>
      <phone>++49 [0]6221/56-32377</phone>
      <email>Peter.Burgard@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <phone>++49 [0]6221/56-37733</phone>
    </contact_backup>
    <investigator>
      <last_name>Georg Hoffmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Burgard, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Stricker</last_name>
      <phone>+41 44-266-7111</phone>
      <email>Tamar.stricker@kispi.uzh.ch</email>
    </contact>
    <investigator>
      <last_name>Matthias Baumgartner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamar Stricker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/ucdc/</url>
    <description>Urea Cycle Disorders Consortium website</description>
  </link>
  <reference>
    <citation>Patrick TB, Richesson R, Andrews JE, Folk LC. SNOMED CT coding variation and grouping for &quot;other findings&quot; in a longitudinal study on urea cycle disorders. AMIA Annu Symp Proc. 2008 Nov 6:11-5.</citation>
    <PMID>18998949</PMID>
  </reference>
  <reference>
    <citation>Richesson RL, Lee HS, Cuthbertson D, Lloyd J, Young K, Krischer JP. An automated communication system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants. Contemp Clin Trials. 2009 Jan;30(1):55-62. doi: 10.1016/j.cct.2008.09.002. Epub 2008 Sep 7.</citation>
    <PMID>18804556</PMID>
  </reference>
  <reference>
    <citation>Mitchell S, Ellingson C, Coyne T, Hall L, Neill M, Christian N, Higham C, Dobrowolski SF, Tuchman M, Summar M; Urea Cycle Disorder Consortium. Genetic variation in the urea cycle: a model resource for investigating key candidate genes for common diseases. Hum Mutat. 2009 Jan;30(1):56-60. doi: 10.1002/humu.20813.</citation>
    <PMID>18666241</PMID>
  </reference>
  <reference>
    <citation>Jain-Ghai S, Nagamani SC, Blaser S, Siriwardena K, Feigenbaum A. Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported? Mol Genet Metab. 2011 Sep-Oct;104(1-2):107-11. doi: 10.1016/j.ymgme.2011.06.025. Epub 2011 Jul 13. Erratum in: Mol Genet Metab. 2012 Jan;105(1):159.</citation>
    <PMID>21802329</PMID>
  </reference>
  <reference>
    <citation>Wilson JM, Shchelochkov OA, Gallagher RC, Batshaw ML. Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. Mol Genet Metab. 2012 Feb;105(2):263-5. doi: 10.1016/j.ymgme.2011.10.016. Epub 2011 Nov 7.</citation>
    <PMID>22129577</PMID>
  </reference>
  <reference>
    <citation>Burrage LC, Jain M, Gandolfo L, Lee BH; Members of the Urea Cycle Disorders Consortium, Nagamani SC. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. Mol Genet Metab. 2014 Sep-Oct;113(1-2):131-5. doi: 10.1016/j.ymgme.2014.06.005. Epub 2014 Jul 3.</citation>
    <PMID>25042691</PMID>
  </reference>
  <reference>
    <citation>Burrage LC, Sun Q, Elsea SH, Jiang MM, Nagamani SC, Frankel AE, Stone E, Alters SE, Johnson DE, Rowlinson SW, Georgiou G; Members of Urea Cycle Disorders Consortium, Lee BH. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. Hum Mol Genet. 2015 Nov 15;24(22):6417-27. doi: 10.1093/hmg/ddv352. Epub 2015 Sep 10.</citation>
    <PMID>26358771</PMID>
  </reference>
  <reference>
    <citation>Krivitzky LS, Walsh KS, Fisher EL, Berl MM. Executive functioning profiles from the BRIEF across pediatric medical disorders: Age and diagnosis factors. Child Neuropsychol. 2016;22(7):870-88. doi: 10.1080/09297049.2015.1054272. Epub 2015 Jul 6.</citation>
    <PMID>26143938</PMID>
  </reference>
  <reference>
    <citation>Waisbren SE, He J, McCarter R. Assessing Psychological Functioning in Metabolic Disorders: Validation of the Adaptive Behavior Assessment System, Second Edition (ABAS-II), and the Behavior Rating Inventory of Executive Function (BRIEF) for Identification of Individuals at Risk. JIMD Rep. 2015;21:35-43. doi: 10.1007/8904_2014_373. Epub 2015 Feb 25.</citation>
    <PMID>25712381</PMID>
  </reference>
  <results_reference>
    <citation>Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee HS, McCarter RJ, Krischer JP, Batshaw ML; Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008 Aug;94(4):397-402. doi: 10.1016/j.ymgme.2008.05.004. Epub 2008 Jun 17.</citation>
    <PMID>18562231</PMID>
  </results_reference>
  <results_reference>
    <citation>Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res. 2009 Jul;66(1):96-101. doi: 10.1203/PDR.0b013e3181a27a16.</citation>
    <PMID>19287347</PMID>
  </results_reference>
  <results_reference>
    <citation>Morgan TM, Schlegel C, Edwards KM, Welch-Burke T, Zhu Y, Sparks R, Summar M; Urea Cycle Disorders Consortium. Vaccines are not associated with metabolic events in children with urea cycle disorders. Pediatrics. 2011 May;127(5):e1147-53. doi: 10.1542/peds.2010-1628. Epub 2011 Apr 11. Erratum in: Pediatrics. 2011 Aug;128(2):390.</citation>
    <PMID>21482610</PMID>
  </results_reference>
  <results_reference>
    <citation>Ah Mew N, Krivitzky L, McCarter R, Batshaw M, Tuchman M; Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network. Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. J Pediatr. 2013 Feb;162(2):324-9.e1. doi: 10.1016/j.jpeds.2012.06.065. Epub 2012 Aug 15.</citation>
    <PMID>22901741</PMID>
  </results_reference>
  <results_reference>
    <citation>Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, Lemons C, Baumgartner M, Cederbaum S, Diaz GA, Feigenbaum A, Gallagher RC, Harding CO, Kerr DS, Lanpher B, Lee B, Lichter-Konecki U, McCandless SE, Merritt JL, Oster-Granite ML, Seashore MR, Stricker T, Summar M, Waisbren S, Yudkoff M, Batshaw ML. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab. 2010;100 Suppl 1:S97-105. doi: 10.1016/j.ymgme.2010.01.014. Epub 2010 Feb 10. Review.</citation>
    <PMID>20188616</PMID>
  </results_reference>
  <results_reference>
    <citation>Gallagher RC, Lam C, Wong D, Cederbaum S, Sokol RJ. Significant hepatic involvement in patients with ornithine transcarbamylase deficiency. J Pediatr. 2014 Apr;164(4):720-725.e6. doi: 10.1016/j.jpeds.2013.12.024. Epub 2014 Jan 30.</citation>
    <PMID>24485820</PMID>
  </results_reference>
  <results_reference>
    <citation>Batshaw ML, Tuchman M, Summar M, Seminara J; Members of the Urea Cycle Disorders Consortium. A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014 Sep-Oct;113(1-2):127-30. doi: 10.1016/j.ymgme.2014.08.001. Epub 2014 Aug 10. Review.</citation>
    <PMID>25135652</PMID>
  </results_reference>
  <results_reference>
    <citation>McGuire PJ, Lee HS; members of the Urea Cycle Disorders Consoritum, Summar ML. Infectious precipitants of acute hyperammonemia are associated with indicators of increased morbidity in patients with urea cycle disorders. J Pediatr. 2013 Dec;163(6):1705-1710.e1. doi: 10.1016/j.jpeds.2013.08.029. Epub 2013 Sep 29.</citation>
    <PMID>24084106</PMID>
  </results_reference>
  <results_reference>
    <citation>Waisbren SE, Gropman AL; Members of the Urea Cycle Disorders Consortium (UCDC), Batshaw ML. Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium. J Inherit Metab Dis. 2016 Jul;39(4):573-84. doi: 10.1007/s10545-016-9942-0. Epub 2016 May 23.</citation>
    <PMID>27215558</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2005</study_first_submitted>
  <study_first_submitted_qc>October 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Research Institute</investigator_affiliation>
    <investigator_full_name>Andrea Gropman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Urea</keyword>
  <keyword>Inherited metabolic disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Brain Diseases, Metabolic</mesh_term>
    <mesh_term>Brain Diseases, Metabolic, Inborn</mesh_term>
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

